Navigating the Complexities of Generics and Biosimilars in Portugal
By Staff Writer
December 5, 2023
The Role and Mission of APOGEN
APOGEN, or the Portuguese Association of Generics and Biosimilars Medicines, is a non-profit organisation founded in 2003. Representing pharmaceutical companies in the Portuguese market, APOGEN’s mission is to promote the concepts of generic and biosimilar medicines. They establish dialogues with stakeholders, including the government and policy makers. They advocate for a more competitive pharmaceutical market.
The Importance of a Thriving Generics Industry
The significance of a thriving generics industry cannot be overstated. However, the introduction of unsustainable cost containment measures has led to product and company withdrawals from the market. This has highlighted the need for greater awareness of the risk of industry unsustainability.
Overcoming Roadblocks to Greater Generic Penetration
Despite generics penetration standing at 51 percent in units and 64.7 percent in the competitive market, Portugal still has significant potential for growth. Barriers such as doubts about the quality and efficacy of generics among doctors, and the pricing and reimbursement system, need to be addressed.
The Future of Generics and Biosimilars in Portugal
Biosimilar medicines offer increased access to life-altering biologic therapies. Although Portugal has implemented measures to facilitate the entry of biosimilar medicines, concerns remain about measures that could compromise the maintenance and launch of new biosimilars in the country.
The EU Pharma Package and APOGEN’s Aspirations
The recent proposal for amending the Pharmaceutical Directive and Regulation signifies a positive move towards the reform of EU pharmaceutical policy. APOGEN urges co-legislators to endorse policies that increase the uptake of generic, biosimilar, and value-added medicines. Therefore, they should also promote timely competition. It’s essential that the adjustment of incentives offers legal certainty for applications of generic and biosimilar medicines.
Bringing Essential Medicine Manufacturing Back to Europe
In conclusion, the outsourcing of essential medicine manufacturing to Asia has proven problematic during times of crisis. Portugal, with its highly skilled workforce and competitive labour costs, could play a crucial role in bringing essential medicine manufacturing back to Europe.
🧠 Are we truly listening to patients when innovating for brain health?
Recent insights underscore the importance of patient experience data (PXD) in shaping research and regulatory decisions around neurological disorders. By embedding PXD at every stage of healthcare innovation, we can align new therapies with what truly matters to patients, enhancing outcomes and access.
Dive into the transformative potential of patient-centered data and how it’s setting a new standard in health economics and outcomes research.
🩺 Is the removal of thimerosal from flu vaccines a step towards safer immunization or a move that could undermine public trust?
The recent decision by the U.S. Department of Health and Human Services to eliminate this mercury-based preservative has sparked a heated debate. While aiming to protect vulnerable populations, it raises questions about the impact on public perception and vaccine confidence.
Dive into the implications of this controversial policy shift and what it means for the future of vaccination practices.
🤔 Are you up to date with the latest strategies for managing Type 2 Diabetes?
A recent comprehensive review jumps into the evolving landscape of Type 2 diabetes treatment, emphasizing individualized care through lifestyle modifications, effective medications, and emerging therapies. Discover how personalized approaches can not only improve health outcomes but also mitigate complications associated with this chronic condition.
Curious to learn more? Click through for insights that could transform your understanding of diabetes management!
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
